Bellicum Pharmaceuticals, Inc. (BLCM)
Stock Price Chart
Key Info
| Market Cap | 35.06M |
| Revenue (ttm) | 5.24M |
| Net Income (ttm) | -86.63M |
| Shares Out | 5.06M |
| EPS (ttm) | -17.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 13, 2020 |
| Last Price | $6.93 |
| Previous Close | $7.04 |
| Change ($) | -0.11 |
| Change (%) | -1.56% |
| Day's Open | 7.04 |
| Day's Range | 6.76 - 7.07 |
| Day's Volume | 20,435 |
| 52-Week Range | 3.32 - 27.90 |
More Stats
| Market Cap | 35.06M |
| Enterprise Value | n/a |
| Earnings Date (est) | Nov 4, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 5.06M |
| Float | 5.03M |
| EPS (basic) | -20.07 |
| EPS (diluted) | -17.50 |
| FCF / Share | -9.36 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 428,183 |
| Short Ratio | 8.88 |
| Short % of Float | 8.07% |
| Beta | 2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 6.70 |
| PB Ratio | 40.34 |
| Revenue | 5.24M |
| Operating Income | -67.48M |
| Net Income | -86.63M |
| Free Cash Flow | -47.28M |
| Net Cash | 38.29M |
| Net Cash / Share | 7.57 |
| Gross Margin | -1,056.68% |
| Operating Margin | -1,288.67% |
| Profit Margin | -1,885.30% |
| FCF Margin | -903.02% |
| ROA | -50.42% |
| ROE | -6,120.17% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.14 | 1.12 | 0.19 | 0.39 | 0.28 | 1.78 | 1.94 | 1.47 |
| Revenue Growth | 537.77% | 505.41% | -52.32% | 37.59% | -84.16% | -8.29% | 32.01% | - |
| Gross Profit | 7.14 | 1.12 | 0.19 | 0.39 | 0.28 | 1.78 | 1.94 | 1.47 |
| Operating Income | -87.36 | -95.47 | -87.39 | -68.38 | -49.14 | -57.84 | -7.92 | -6.27 |
| Net Income | -112 | -98.04 | -91.78 | -69.24 | -48.55 | -83.97 | -7.97 | -6.26 |
| Shares Outstanding | 4.68 | 4.02 | 3.17 | 2.70 | 2.63 | 0.25 | 0.18 | 0.16 |
| Earnings Per Share | -24.01 | -24.37 | -28.90 | -25.70 | -18.40 | -340.40 | -50.50 | -42.60 |
| Operating Cash Flow | -77.57 | -74.78 | -72.98 | -50.44 | -35.73 | -57.31 | -7.61 | -7.74 |
| Capital Expenditures | -0.52 | -1.62 | -12.10 | -7.22 | -5.42 | -0.80 | -0.37 | -2.05 |
| Free Cash Flow | -78.09 | -76.40 | -85.08 | -57.66 | -41.15 | -58.11 | -7.98 | -9.79 |
| Cash & Equivalents | 93.82 | 93.00 | 105 | 113 | 94.06 | 192 | 11.17 | 1.63 |
| Total Debt | 38.04 | 35.96 | 35.11 | 20.39 | 0.13 | - | 0.80 | 0.45 |
| Net Cash / Debt | 55.78 | 57.04 | 69.98 | 93.03 | 93.93 | 192 | 10.37 | 1.18 |
| Assets | 116 | 122 | 136 | 132 | 160 | 196 | 14.94 | 5.19 |
| Liabilities | 121 | 53.02 | 50.88 | 35.46 | 8.39 | 4.16 | 3.17 | 3.00 |
| Book Value | -26.22 | 68.48 | 84.65 | 96.57 | 152 | 192 | -28.15 | -19.47 |
Company Profile
Company Details
| Full Name | Bellicum Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 107 |
| CEO | Richard A. Fair |
Stock Information
| Ticker Symbol | BLCM |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: BLCM |
| IPO Date | December 18, 2014 |
Description
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.